New treatments for aggressive breast cancer
Novel Targeted Therapeutics for Breast Cancer
This study is looking at a new way to treat triple negative breast cancer by targeting a specific gene that helps tumors grow, with the hope of improving survival for patients facing this tough diagnosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10892145 on NIH RePORTER |
What this research studies
This research focuses on developing targeted therapies for triple negative breast cancer (TNBC), a subtype known for its poor prognosis and lack of effective treatments. The team has identified a gene called Eukaryotic Elongation Factor 2-Kinase (EF2K) that is overexpressed in many TNBC patients and linked to tumor growth and progression. By using advanced genetic techniques in animal models, they aim to create therapies that specifically target EF2K, potentially improving survival rates for patients with this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those with high levels of EF2K expression.
Not a fit: Patients with other subtypes of breast cancer or those whose tumors do not express EF2K may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments that significantly improve survival rates for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting specific molecular pathways in cancer, suggesting that this approach could be effective, although targeting EF2K specifically is a novel strategy.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Ozpolat, Bulent — Methodist Hospital Research Institute
- Study coordinator: Ozpolat, Bulent
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.